	US 12,448,416 B2
	Stabilized coronavirus spike (s) protein immunogens and related vaccines
Linling He, San Diego, CA (US); Jiang Zhu, San Diego, CA (US); and Ian A. Wilson, La Jolla, CA (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US)
Filed by The Scripps Research Institute, La Jolla, CA (US)
Filed on Nov. 7, 2023, as Appl. No. 18/503,260.
Application 18/503,260 is a continuation of application No. 17/087,704, filed on Nov. 3, 2020, granted, now 11,845,777.
Application 17/087,704 is a continuation of application No. 17/019,825, filed on Sep. 14, 2020, granted, now 10,906,944, issued on Feb. 2, 2021.
Claims priority of provisional application 63/045,557, filed on Jun. 29, 2020.
Prior Publication US 2024/0140993 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/215 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/215 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)]

20 Claims

1. An engineered immunogen polypeptide derived from the spike(S) protein of a coronavirus, comprising an altered soluble S sequence that has modifications relative to wildtype soluble S sequence of the coronavirus that stabilize the prefusion S structure, wherein the modifications comprise (a) a mutation that inactivates the S1/S2 cleavage site, and (b) a truncation of the heptad repeat 2 region (HR2).